Researchers have discovered a key role played by IGFBP2 in regulating the action of EGFR in glioblastoma cells, allowing them to become resistant to drug treatments. This finding offers new hope for developing targeted therapies that target both EGFR and IGFBP2.
A team of researchers has developed a platform to rapidly identify effective drug combinations for lung cancer patients with resistant tumors. The NFCR-supported study uses cells taken from patient tumors and treats them with various drug combinations to find the most effective treatments.
A new report highlights 100 companies created from federally funded university research, driving innovation and job creation. The companies' success is attributed to the nurturing ecosystem of research universities, providing access to essential tools like technology transfer offices and business incubators.